Autologous bone marrow mononuclear cells (Vinmec Research Institute of Stem Cell and Gene Technology)

自体骨髓单个核细胞疗法（Vinmec Research Institute of Stem Cell and Gene Technology）

Report date: 2023/01/02 21:19:30

Base Information

Drug NameAutologous bone marrow mononuclear cells (Vinmec Research Institute of Stem Cell and Gene Technology)

Drug Alias Nameautologous BM-MNCs

ClassificationCell and gene therapy > Cell therapy > Donor > AutologousCell and gene therapy > Cell therapy > Immune system cell therapy > Leukocyte cell therapy > Monocyte cell therapyCell and gene therapy > Cell therapy > Source of cells > Bone Marrow-derived

Mechanisms of ActionCell replacements

TargetsNot applicable

Therapy Area/IndicationsAutistic DisorderAutism Spectrum DisorderBiliary Atresia

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryVietnam

CombinationsNo

Global Highest StatusPhase 2 Clinical

Highest Status in ChinaN/A

Originator CompaniesVinmec Research Institute Of Stem Cell And Gene Technology

China Registration ClassN/A

Develop Information

Active CompaniesVinmec Research Institute Of Stem Cell And Gene Technology

Inactive CompaniesN/A

Active IndicationsAutistic DisorderAutism Spectrum DisorderBiliary Atresia

Inactive IndicationsN/A

Other Information

ATC CodeN/A